Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage

References

• Hwang ST, Janik JE, Jaffe ES, et al. Mycosis fungoides and Sezary syndrome. Lancet 2008;371:945–957.
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768–3785.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Ferreri AJ, Cerroni L. Mycosis fungoides. Crit Rev Oncol Hematol 2008;65:172–182.
   PubMed Web of Science ®Google Scholar
• Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009;1:a001883.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011;2011:603925.
   Google Scholar
• Manfe V, Biskup E, Johansen P, et al. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53. J Invest Dermatol 2012;132:1487–1496.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012;119:3668–3683.
   PubMed Web of Science ®Google Scholar
• Cheung KJ, Horsman DE, Gascoyne RD. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol 2009;146:257–269.
   PubMed Web of Science ®Google Scholar
• Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005;331:834–842.
   PubMed Web of Science ®Google Scholar
• Foster BA, Coffey HA, Morin MJ, et al. Pharmacological rescue of mutant p53 conformation and function. Science 1999;286:2507–2510.
   PubMed Web of Science ®Google Scholar
• Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282–288.
   PubMed Web of Science ®Google Scholar
• Peng Y, Li C, Chen L, et al. Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003;22:4478–4487.
   PubMed Web of Science ®Google Scholar
• Kaltoft K, Bisballe S, Dyrberg T, et al. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 1992;28A:161–167.
   PubMed Web of Science ®Google Scholar
• Kaltoft K, Bisballe S, Rasmussen HF, et al. A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 1987; 279:293–298.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Carney DN, Bunn PA, et al. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 1980;55:409–417.
   PubMed Web of Science ®Google Scholar
• Kamstrup MR, Gjerdrum LM, Biskup E, et al. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood 2010;116:2504–2512.
   PubMed Web of Science ®Google Scholar
• Wang F, Liu J, Robbins D, et al. Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells. Apoptosis 2011;16:301–310.
   PubMed Web of Science ®Google Scholar
• Pietsch EC, Sykes SM, McMahon SB, et al. The p53 family and programmed cell death. Oncogene 2008;27:6507–6521.
   PubMed Web of Science ®Google Scholar
• Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol 2010;20:14–24.
   PubMed Web of Science ®Google Scholar
• Garbett NC, Graves DE. Extending nature's leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents 2004;4:149–172.
   PubMedGoogle Scholar
• Poljakova J, Frei E, Gomez JE, et al. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett 2007;252:270–279.
   PubMed Web of Science ®Google Scholar
• Stiborova M, Poljakova J, Martinkova E, et al. Ellipticine cytotoxicity to cancer cell lines - a comparative study. Interdiscip Toxicol 2011;4:98–105.
   PubMedGoogle Scholar
• Kim JY, Lee SG, Chung JY, et al. Ellipticine induces apoptosis in human endometrial cancer cells: the potential involvement of reactive oxygen species and mitogen-activated protein kinases. Toxicology 2011;289:91–102.
   PubMed Web of Science ®Google Scholar
• Podhorecka M, Skladanowski A, Bozko P. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids 2010;2010. pii: 920161
   PubMedGoogle Scholar
• Kuo YC, Kuo PL, Hsu YL, et al. Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci 2006;78:2550–2557.
   PubMed Web of Science ®Google Scholar
• Martinkova E, Maglott A, Leger DY, et al. alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer 2010;127:1240–1248.
   PubMed Web of Science ®Google Scholar
• Dalton LK, Demerac S, Elmes BC, et al. Synthesis of the tumour-inhibitory alkaloids ellipticine, 9-methoxyellipticine and related pyrido[4,3-b]carbazoles. Aust J Chem 1967;20:2715–2727.
   Web of Science ®Google Scholar
• Kizek R, Adam V, Hrabeta J, et al. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. Pharmacol Ther 2012;133:26–39.
   PubMed Web of Science ®Google Scholar
• Poljakova J, Eckschlager T, Hrabeta J, et al. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol 2009;77:1466–1479.
   PubMed Web of Science ®Google Scholar
• Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010;40:179–204.
   PubMed Web of Science ®Google Scholar
• Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 2004;567: 1–61.
   PubMed Web of Science ®Google Scholar
• Chastain PD 2nd, Nakamura J, Swenberg J, et al. Nonrandom AP site distribution in highly proliferative cells. FASEB J 2006;20: 2612–2614.
   PubMed Web of Science ®Google Scholar
• Hazra TK, Das A, Das S, et al. Oxidative DNA damage repair in mammalian cells: a new perspective. DNA Repair (Amst) 2007;6: 470–480.
   PubMed Web of Science ®Google Scholar
• Niki E, Noguchi N. Dynamics of antioxidant action of vitamin E. Acc Chem Res 2004;37:45–51.
   PubMed Web of Science ®Google Scholar
• Frei B. Reactive oxygen species and antioxidant vitamins: mechanisms of action. Am J Med 1994;97: 5S–13S; discussion 22S–28S.
   PubMed Web of Science ®Google Scholar